AMR: Big Pharma sets up US$1bn Fund
After leaving the field of antimicrobials 20 years ago because other areas offered better returns, 23 pharma companies and the Novo Foundation have launched a US$1bn fund to fight antimicrobial resistance (AMR).
ADVERTISEMENT
New Search
If you are not happy with the results below please do another search
76 search results for: MSD
Is AMR the next, but hidden, crisis?
/in BackgroundWith the coronavirus pandemic mounting, experts are warning of AMR as being the next, hidden crisis.
EMA greenlights 15 new meds
/in Latest NewsThe EMA’s human medicines committee (CHMP) recommended fifteen medicines for approval at its January 2020 meeting.
Ipsen: New VP and CMO incoming
/in AppointmentsIpsen has named steven Hildemann as Executive Vice President, Chief Medical Officer, Head of Global Medical Affairs and Pharmacovigilance, effective March 2020.
Merck and 4SC collaborate in immunooncology
/in Latest News4SC AG and Merck KgaA have signed a supply agreement to start clinical tests of Merck’s checkpoint blocker avelumab plus 4SC’s HDAC I blocker domatinostat.
NSCLC: Bemcentinib + anti-PD1 triple PFS
/in Latest NewsBergen Bio ASA’s Axl kinase blocker bemcentinib in combination with MSD’s pembrolizumab has met the primary endpoint in a Phase II study in patients with non small cell lung cancer (NSCLC).
New players to step into the AMR field
/in BackgroundDespite challenging markets new players are entering the field to advance drug development in the fight against antimicrobial resistance.
The AMR business (Part II)
/in BackgroundSMEs active in antibiotic development are trying to adapt to the uncertain AMR business. Meanwhile, the European IMI AMR accelerator kicked off.
Researchers identify CTLA-4 response marker
/in Latest NewsGerman and US researchers have found a biomarker that identifies tumours responding to CTLA-4 checkpoint blockers.
Wellington Partners launch €210m Life Sciences fund
/in Latest NewsWellington Partners has closed its largest Life Sciences Fund ever. The VC specialist outperformed its intial target of raising €120m to €150m and closed at €210m.